#hypoparathyroidism-drug-market-share

[marketingseos]

#hypoparathyroidism-drug-market-share

[sayali13]

Hair Dryer Market Size, Share, Key Drivers, Trends, Challenges and Competitive Analysis

"Data Bridge Market research has recently issued comprehensive industry research on Global Hair Dryer Market Market which includes growth analysis, regional marketing, challenges, opportunities, and drivers analysed in the report. The market insights gained through this Hair Dryer Market market research analysis report facilitates more defined understanding of the market landscape, issues that may interrupt in the future, and ways to position definite brand excellently.

An analysis of competitors is conducted very well in the reliable Hair Dryer Market Market report which covers vital market aspects about the key players. Moreover, the report gives out market potential for many regions across the globe based on the growth rate, macroeconomic parameters, consumer buying patterns, their preferences for particular product and market demand and supply scenarios. It gives significant information and data pertaining to their insights in terms of finances, product portfolios, investment plans, and marketing and business strategies. Detailed market analysis has been performed here with the inputs from industry experts.

Access Full 350 Pages PDF Report @

Data Bridge Market Research analyses that the hair dryer market which was growing at a value of 7.93 billion in 2021 and is expected to reach the value of USD 12.45 billion by 2029, at a CAGR of 5.80% during the forecast period of 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, import/export analysis, pricing analysis, production consumption analysis, and consumer behaviour.

Some of the major players operating in the hair dryer market are:

Panasonic India (China)

Dyson (Singapore)

Procter & Gamble (U.S.)

Groupe SEB (France)

Coty Inc. (U.S.)

Koninklijke Philips N.V. (Netherlands)

VEGA (India)

Andis Company Inc. (U.S.)

Revlon, Inc. (U.S.)

Helen of Troy Limited (U.S.)

Spectrum Brands, Inc. (U.S.)

Lunata Beauty (U.S.)

Havells India Limited (India)

Conair Corporation (U.S.)

Highlights of TOC:

Chapter 1: Market overview

Chapter 2: Global Hair Dryer Market Market

Chapter 3: Regional analysis of the Global Hair Dryer Market Market industry

Chapter 4: Hair Dryer Market Market segmentation based on types and applications

Chapter 5: Revenue analysis based on types and applications

Chapter 6: Market share

Chapter 7: Competitive Landscape

Chapter 8: Drivers, Restraints, Challenges, and Opportunities

Chapter 9: Gross Margin and Price Analysis

Key Questions Answered with this Study

1) What makes Hair Dryer Market Market feasible for long term investment?

2) Know value chain areas where players can create value?

3) Teritorry that may see steep rise in CAGR & Y-O-Y growth?

4) What geographic region would have better demand for product/services?

5) What opportunity emerging territory would offer to established and new entrants in Hair Dryer Market Market?

6) Risk side analysis connected with service providers?

7) How influencing factors driving the demand of Hair Dryer Marketin next few years?

8) What is the impact analysis of various factors in the Global Hair Dryer Market Market growth?

9) What strategies of big players help them acquire share in mature market?

10) How Technology and Customer-Centric Innovation is bringing big Change in Hair Dryer Market Market?

Browse Trending Reports:

Europe Electronic Drug Delivery Systems Market

North America Electronic Drug Delivery Systems Market

Asia-Pacific Electronic Drug Delivery Systems Market

Middle East and Africa Electronic Drug Delivery Systems Market

Hypoparathyroidism Treatment Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: [phone]

UK: [phone]

APAC : [phone]

Email: [email protected]"

#Hair Dryer

[researchtrendingmarket-blog]

Hypoparathyroidism Drug Market - Industry Trends - Forecast to 2026

Global hypoparathyroidism drug market is expected to grow at a substantial growth of 8.1% CAGR in the forecast period of 2019-2026. The emergence of drugs used in thyroid diseases, increases number of   thyroid cancer, development of newer technologies and vulnerable hypoparathyroidism patients enhancing the market growth.

Get Sample Report at :

https://bit.ly/2Db68Dk

#Hypoparathyroidism Drug Market #Hypoparathyroidism Drug Market share #Hypoparathyroidism Drug Market news #Hypoparathyroidism Drug Market report #Hypoparathyroidism Drug Market growth #Hypoparathyroidism Drug Market forecast

[researchtrendingnews]

Hypoparathyroidism Drug Market - Industry Trends - Forecast to 2026

Global hypoparathyroidism drug market is expected to grow at a substantial growth of 8.1% CAGR in the forecast period of 2019-2026.  The emergence of drugs used in thyroid diseases, increases number of   thyroid cancer, development of newer technologies and vulnerable hypoparathyroidism patients enhancing the market growth.

https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hypoparathyroidism-drug-market

#Hypoparathyroidism Drug Market #Hypoparathyroidism Drug Market share #Hypoparathyroidism Drug Market size #Hypoparathyroidism Drug Market trends #Hypoparathyroidism Drug Market news #Hypoparathyroidism Drug Market report #Hypoparathyroidism Drug Market growth #Hypoparathyroidism Drug Market forecast

[alwayssweatycolor]

Hypercalcemia Treatment Market (COVID-19 Impact) Insights 2021, Size, Global Trends, Industry Share, Growth Rate, Top Players, Business Opportunities, Demand Forecast 2026 | FMI

The global hypoparathyroidism treatment landscape that only gained much significance post the FDA approval of Natpara in 2015, is projected grow at a rather robust CAGR of approximately 8% through 2026. As per a recent in-depth analysis by Future Market Insights (FMI), the valuation of global hypoparathyroidism treatment market is expected to stand at US$ 663.7 Million in 2019. Although the growth rate is expected to showcase similar trends, the global hypoparathyroidism treatment market is still in its infancy, with most of the treatment options in various phases of clinical programs.

"The global hypoparathyroidism treatment market holds the potential to exceed the US$ 1.1 Billion mark by 2026, in terms of revenue. The treatment landscape for hypoparathyroidism-a rare endocrine disorder, characterized by high phosphate and low calcium levels, during low or inappropriately normal PTH level-will mostly be driven by increasing incidences of thoracic surgeries and cancer combined with Rising screening rates of thyroid diseases. Moreover, considering the rarity, hypoparathyroidism was classified as an orphan disease in European Union and United States. Considering which, favorable government schemes relating to orphan drug combined with tax incentives such as tax credits for qualified clinical trials and market exclusivity upon regulatory approval are some expected to translate into high return on investment for companies innovating drugs in hypoparathyroidism treatment market", explains a senior analyst.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7857

A Comprehensive Analysis of the Pipeline Clinical Programs for Hypoparathyroidism Treatment by FMI, Reveals:

There are around 47 ongoing clinical programs, globally, at different stages of development, wherein, 43 are interventional studies and 19 involve API with high potential market equity.

Most of these clinical programs are aimed at evaluating the efficacy of different treatment lines for hypoparathyroidism treatment, involving Calcitriol, calcium supplements, and magnesium.

Moreover, since hypoparathyroidism is the state of decreased secretion or activity of parathyroid hormone (PTH), close to 12 such clinical trials are focused on parathyroid hormone.

Of the total active clinical programs, phase III and phase IV clinical trials, collectively account for approximately 37.3 percent.

FMI, in its market study on hypoparathyroidism treatment also indicates that nearly 7 percent clinical programs stand terminated, suspended or withdrawn given their side-effects and failed efficacy.

Although approximately 45 percent clinical trials stand completed, most of the trials do not meet or partially meet the hypoparathyroidism treatment guidelines set by regulatory authorities.

Of the 47 percent active clinical trials, Shire continues to remain the leader in Hypoparathyroidism treatment clinical space with over 7 such active programs, followed by Entera Bio Ltd.

North America, accounting for nearly 57 percent leads the clinical trials landscape for hypoparathyroidism treatment, followed by Europe at 29 percent, as in 2017.

Preview Analysis On : Hypoparathyroidism Treatment Market Segmentation By Drug Class - parathyroid hormone, vitamin D analogue and calcium supplements; Route of Administration - Oral, Parenteral; Distribution Channels - Retail pharmacy, Hospital pharmacy, Online sales: https://www.futuremarketinsights.com/reports/hypoparathyroidism-treatment-market

Natpara Holds Approximately $2 Billion Market Opportunity, Reveals FMI

Considering a significant patient pool for hypoparathyroidism treatment and extremely low competition, Natpara is projected to showcase maximum revenue opportunity, with its demand expanding at magnificent CAGR of 145.8 percent, in the last few years.

Ever since its approval in 2015, Natpara has demonstrated a year-on-year growth of 72.8 percent through 2017

Despite labeling restrictions (Natpara Risk Evaluation and Mitigation Strategy (REMS) Program), considering Natpara's side effects including possible bone cancer (osteosarcoma) and high blood calcium (hypercalcemia), the U.S. currently accounts for 99 % of the total Natpara sales. In EU, sales of Natpara reached US$ 109.8 Million, in H1 2018-both the regions representing substantial revenue growth opportunities.

The bioengineered replacement biologic is also projected to drive significnat adoption of drug titration based on individual cases, translating into personalized medicines.

Hypoparathyroidism Treatment Market Showcases a Fairly Consolidated Landscape

Largely dominated by branded drug manufacturers, the competition in Hypoparathyroidism Treatment Market is projected to remain low through the forecast period of 2018-2026. Key leaders including EnteraBio Ltd., Shire-NPS Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd. account for nearly 50 percent market share, with a key focus on developing novel treatment options for hypoparathyroidism. Apart from new product innovations, key players are also expected to take the 'strategic acquisitions to expand global presence combined with increasing distribution channel' route to reach untreated patient pool. In Asia, India accounts for the highest hypoparathyroidism-related mortality incidences, compared to any other region, arising from lack of sufficient screening and treatment lines. However, on the other hand, large unmet treatment needs combined with long clinical trials, will translate into patients opting for alternative medications available in the form of calcium and vitamin generics, thereby increasing the buyer advantage.

Request Report TOC @ https://www.futuremarketinsights.com/askus/rep-gb-7857

Insights Drawn From Segmentation Analysis of Hypoparathyroidism Treatment Market

While US dominates the hypoparathyroidism treatment landscape with 86 percent market share considering reasons mentioned, Asia Pacific is also projected to witness strong growth.

In terms of drug class, calcium supplements will remain the most preferred, with 38 percent market share. PTH will also showcase substantial growth rate.

On the basis of route of administration, parenteral method will remain the fastest growth segment, compared to oral methods.

Sales of hypoparathyroidism treatment drugs through retail pharmacies will generate maximum revenue, followed by hospital pharmacies.

More from Healthcare, Pharmaceuticals and Medical devices:

Counterfeit Drug Detection Device Market Analysis

Bone Growth Stimulators Market Analysis

Peripheral T Cell Lymphoma Treatment Market Analysis

#Hypercalcemia Treatment Market #Hypercalcemia Treatment Market Size #Hypercalcemia Treatment Market Value

[riddhiochani]

Hypoparathyroidism Treatment Market is estimated to value over USD xx billion by 2027 end and register a CAGR of 8% from the forecast period 2020-2027.

The report initiates from the outline of business surroundings and explains the commercial summary of chain structure. Moreover, it analyses forecast By Drug Class, By Route of Administration, By Region and Hypoparathyroidism Treatment market.

#Hypoparathyroidism Treatment Market Analysis #Hypoparathyroidism Treatment Market Forecast #Hypoparathyroidism Treatment Market Growth

[factmrresearch1]

Calcium Lactate Market Insight

The global calcium lactate market size is expected to witness potential gains in the future, and register a significant CAGR of 1.7% in terms of value over the forecast period (2019 - 2027).

Market Overview

Calcium lactate is a salt that contains two lactate anions for each calcium cation (Ca2+). Calcium lactate is used to prevent and to treat calcium deficiencies such osteoporosis, osteomalacia/rickets, hypoparathyroidism, and latent tetany. Calcium lactate is found in daily dietary supplements as a source of calcium. Lactic acid is neutralized with calcium carbonate or calcium hydroxide to commercially prepare calcium lactate. According to the U.S. Food and Drugs Administration (FDA), calcium lactate can be used in food, except in infant foods and infant formulas, at levels not to exceed current good manufacturing practice. It is used as a firming agent, flavoring agent, leavening agent, stabilizer, and thickener.

Market Dynamics

Increasing prevalence of calcium deficiency and associated diseases is expected to boost growth of the calcium lactate market. According to the International Osteoporosis Foundation, over 200 million people worldwide suffer from osteoporosis. Increasing geriatric population is also expected to contribute to the market size over the forecast period. People above 65 years of age may suffer from calcium deficiency. Calcium supplements in the form of gluconate, lactate, or phosphate can be used to strengthen bones.

However, high consumption of calcium lactate or any calcium supplement may lead to some health risks such as kidney stones, increased risk of prostate cancer, constipation, calcium buildup in blood vessels, and difficulty absorbing iron and zinc. According to the paper ‘Calcium and Calcium Salts’, published in the Journal of The Association of Physicians of India in February 2017, Calcium supplements are generally well tolerated; however, some patients complain of gastrointestinal symptoms, including constipation ,gas, flatulence, and bloating. Such adverse effects of calcium intake can hinder consumption of calcium lactate and affect market growth over the forecast period.  

Antioxidant peptides eliminate free radicals in the human body without harmful effects. Calcium lactate, along with glucose and casein peptone can be used to prepare such antioxidant peptides. Calcium lactate along with urea can also be used as a self-healing agent for cementitious materials crack repair. For instance, a team of researchers from Korea Advanced Institute of Science and Technology used urea–calcium lactate medium to produce CaCO3, which was later used to develop ureolytic/non-ureolytic bacteria co-cultured self-healing agent for repairing cracks in cementitious materials. Such advancements related to calcium lactate can boost its application in the pharmaceuticals and construction industries. Therefore, key players in the market can focus on commercializing such developments to enhance their market share.

Market Outlook

Asia Pacific is the fastest growing market in the global calcium lactate market, with China and India poised as major growth engines. This is attributed to significant growth in the pharmaceutical and food processing industries in the region. North America is also expected to witness significant growth in the calcium lactate market due to presence of major pharmaceutical companies such as Pfizer and Johnson & Johnsons.

Key Players

Key players operating in the global calcium lactate market include, Alfa Chemical Corporation, Wego Chemicals & Minerals Corp., Haviland Enterprises, Inc., and Action Labs Inc.

Request the sample copy of here: https://www.coherentmarketinsights.com/insight/request-sample/2724

Download the PDF Brochure here: https://www.coherentmarketinsights.com/insight/request-pdf/2724

Buy now the market research report here: https://www.coherentmarketinsights.com/insight/buy-now/2724

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

 What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

 Explore CMI Services here

Contact Us:

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: [phone]

Email: [email protected]

Source: 

https://www.coherentmarketinsights.com/ongoing-insight/calcium-lactate-market-2724

[athiranair23]

Hypercalcemia Treatment Market Analysis (2020-2027)

Hypercalcemia is characterized by increased level of calcium in the blood. The condition can be life-threatening and is associated with neoplastic diseases. Hypocalcemic drugs are used for the treatment of hypercalcemia.

The global hypercalcemia treatment market is estimated to account for US$ 10,696.6 Mn in terms of value in 2018 and is expected to reach US$ 28,060.0 Mn by the end of 2028.

Global Hypercalcemia Treatment Market: Drivers

High incidence of hypercalcemia is a major factor boosting growth of the global hypercalcemia treatment market. For instance, in the study, ‘Incidence of hypocalcemia and hypercalcemia in hospitalized patients: Is it changing?’, published in the Journal of Clinical and Translational Endocrinology, in September 2018, researchers found that 27.72% of the study patients suffered from hypocalcemia and 4.74% from hypercalcemia. Moreover, 585 cases of hypercalcemia were detected.

Moreover, increasing prevalence of cancer is also expected to aid in growth of the market. For instance, according to the World Health Organization, around 18.1 million new cases and 9.6 million deaths were registered due to cancer worldwide in 2018.

Moreover, favorable reimbursement scenario is also expected to aid in growth of the market. Reimbursements enable lesser out-of-pocket costs of treatment for patients, despite having a low income eligibility. For instance, Amgen has a reimbursement policy on its XGEVA (denosumab injection), in which the company pays the out-of-pocket amount in excess of US$ 25 per dose; up to US$ 10,000 in assistance per calendar year. Approximately 70% of XGEVA patients with commercial or Medicare coverage incurred US$ 0 out-of-pocket cost due to favorable reimbursement policy offered by Amgen, Inc.

North America region held dominant position in the global hypercalcemia treatment market in 2018, accounting for 45.5% share in terms of value, followed by Europe.

Global Hypercalcemia Treatment Market: Restraints

Companies face challenges with regard to locating patients for clinical trials and logistics issues related to institutes conducting trials. Such factors increase the costs incurred in R&D of hypercalcemia treatment, which is expected to hinder growth of the global hypercalcemia treatment market.

Moreover, it is challenging to distinguishing primary hyperparathyroidism from conditions that will not respond to parathyroidectomy, which is also expected to limit growth of the market.

Global Hypercalcemia Treatment Market: Opportunities

Product innovations in hypercalcemia drug types other than bisphosphonates is expected to offer lucrative growth opportunities for players in the global hypercalcemia treatment market. Bisphosphonate is the single largest product being utilized for hypercalcemia treatment. End users have recognized the bisphosphonate therapy as effective. Still, the global hypercalcemia treatment market is yet to witness major product innovations in the product types of calcitonin, calcimimetics, and glucocorticoids.

Improving systems for recognizing hypercalcemia can aid in addressing common causes for delayed diagnosis and treatment of the disease, thereby aiding in growth of the market. Educating patients and providers about the consequences of untreated disease can also help in this regard.

Bisphosphonates segment in the global hypercalcemia treatment market was valued at US$ 7,306.2 Mn in 2018 and is expected to reach US$ 19,798.3 Mn by 2027 at a CAGR of 11.7% during the forecast period.

Market Trends/Key Takeaways

R&D in the treatment of hypercalcemia is augmenting growth of the market. For instance, in July 2019, researchers from Ascendis Pharma A/S, in their study, ‘Design and Preclinical Development of TransCon PTH, an Investigational Sustained?Release PTH Replacement Therapy for Hypoparathyroidism,’ reported that TransCon PTH can be used to normalize blood levels of calcium and phosphate.

Sarcoidosis, a complex disease with no known cause, is linked with hypercalcemia. The study, “Hypercalcemic pancreatitis a rare presentation of sarcoidosis: A case report,” published in the journal Medicine in January 2018, reported a sarcoidosis patient with pancreatitis — inflammation of the pancreas — and hypercalcemia.

Global Hypercalcemia Treatment Market: Competitive Landscape

Major players operating in the global hypercalcemia treatment market include, Bayer Pharma AG, Sun Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Amgen Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Cipla Inc., and XOMA Corporation.

Global Hypercalcemia Treatment Market: Key Developments 

Players in the market are focused on attending various conferences to expand their customer base. For instance, in October 2019, XOMA Corporation presented at the 2019 Cantor Fitzgerald Global Healthcare Conference held in New York.

Request sample copy here :  

https://www.coherentmarketinsights.com/insight/request-sample/3504

Request PDF brochure here:

https://www.coherentmarketinsights.com/insight/request-pdf/3504

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

·        Customized Market Research Services

·        Industry Analysis Services

·        Business Consulting Services

·        Market Intelligence Services

·        Long term Engagement Model

·        Country Specific Analysis

Contact Us:   

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: [phone]

Email : [email protected]

 Reference/Source: https://www.coherentmarketinsights.com/

#neoplasticdiseases #increasedlevelofcalciumintheblood #Healthcare #HypercalcemiaTreatmentMarketAnalysis #CoherentMarketInsights #MarketAnalysis

[market-research-future]

Parathyroid Disorders Market Analysis By Key Players, Development Trend, By 2023

Parathyroid Disorders Market Size, Application And Trends Analysis By Type (Hyperparathyroidism, Parathyroid Cancer, Hypoparathyroidism), Diagnosis (Blood Test, Imaging, Urine Test), Treatment (Surgery, Radiation Therapy, Drugs), End User – Global Forecast Till 2023

Key Players

Some of the key players in the global parathyroid disorders market are Abbott Laboratories, Alcon Laboratories, Inc., Amgen Inc., Bayer Healthcare, Becton, Dickinson and Company, Eli Lilly, Ethicon, Inc., Genentech, Medtronic, Merck, Mylan Laboratories, Novartis, Novo Nordisk, Pfizer, Roche, Smith & Nephew plc, Stryker, Teva Pharmaceutical Industries Ltd., Zimmer Biomet Holdings, Inc., and others.

Market Highlights:

A number of factors such as growing geriatric population, rising prevalence of parathyroid disorders, increasing government assistance, rising healthcare expenditure, improving regulatory framework, and rising funding and reimbursements are propelling the growth of the global parathyroid disorders market.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5451

However, challenges in research and development, side-effects of treatment, the presence of misbranded and spurious drugs, expiration of patented drugs, and poor healthcare system in low and middle-income countries may hamper the growth of the market.

It is estimated that the parathyroid disorders market is expected to grow at a CAGR 6.5% during the forecast period of 2017-2023. Parathyroid hormone plays a significant role in regulating the metabolism of calcium, phosphate, and Vitamin D. The hyperparathyroidism, and hypoparathyroidism are the two most common parathyroid disorders.

Segmentation

The global parathyroid disorders market is segmented on the basis of type, diagnosis, treatment, and end user.

On the basis of the type, the market is classified as hyperparathyroidism (HPT), parathyroid cancer, and hypoparathyroidism. The hyperparathyroidism is further sub-segmented into primary hyperparathyroidism, secondary hyperparathyroidism, and tertiary hyperparathyroidism.

On the basis of the diagnosis, the market is classified as blood tests, imaging tests, and urine tests. The imaging tests is further sub-segmented into CT or CAT (computed axial tomography) scans, MRI (magnetic resonance imaging) scans, X-ray, ultrasound, bone density test, and sestamibi scan.

On the basis of the treatment, the market is classified as surgery, radiation therapy, drugs, and others. The drugs segment is further sub-segmented into calcimimetics, hormone replacement therapy, and bisphosphonates.

On the basis of the end user, the market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.

Regional Analysis:

The Americas dominate the global parathyroid disorders market owing to the rising prevalence of parathyroid disorders and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total healthcare expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.

Europe holds the second position in the parathyroid disorders market. It is expected that the support provided by the government bodies for research & development and improvement in the reimbursement policies in the healthcare is likely to drive the market of the European region.

Browse Detailed TOC at: https://www.marketresearchfuture.com/reports/parathyroid-disorders-market-5451

The Asia Pacific is the fastest growing parathyroid disorders market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total healthcare expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.

The Middle East & Africa holds the least market share due to lack of technical knowledge and poor medical facilities.

Brows More Healthcare Related Research Reports at:

Eyelashes Enhancing Agents Market Size, Growth | Application, 2023

US Medical Sector Contract Electronic Manufacturing Market Research Report- Forecast to 2022 | MRFR

Calciphylaxis Market Research Report Forecast To 2023 | MRFR

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Market Research Future

[phone]

Email: [email protected]

[azveille]

UPDATED : Ascendis Pharma offers positive surprise as its tech not just equals, but improves outcomes in key study

Technology developed by Denmark’s Ascendis Pharma to release a particular drug within the body in a predictable manner at regular intervals without the need for multiple separate administrations has been shown to work well in a late-stage trial in pediatric patients with growth hormone deficiency — validating the company’s platform that is used across its portfolio.

The technology, called TransCon or transient conjugation, comprises an unmodified approved drug, an inert carrier that protects it, and a linker that temporarily binds the two. When bound, the carrier inactivates and shields the parent drug from being released, but once the product is injected into the body, physiologic pH and temperature conditions allow for the predictable dissemination of the active drug — this can be done daily or even half yearly. The tech can be used for systemic administration or locally in areas that are difficult to treat with conventional therapy.

The 161 treatment-naïve-patient-trial, called heiGHt, compared the once-weekly TransCon growth hormone (hGH) against a daily growth hormone — Pfizer’s Genotropin — in children with growth hormone deficiency, an orphan disease caused by the insufficient production of growth hormone by the pituitary gland that is characterized by short stature, metabolic abnormalities, psychosocial challenges and cognitive gaps.

TransCon hGH is designed to deliver unmodified hGH — the same growth hormone used in daily therapies — at a predictable rate over one week. Currently in the United States and Europe, patients must contend with daily hGH injections resulting in thousands of injections over time, which often leads to poor patient compliance, the company said.

Trial data showed that Ascendis’ product not only met the main goal of non-inferiority in annualized height velocity (a measure of speed of growth) at 52 weeks, but actually proved superior to daily hGH. These results could constitute a home run, considering various analysts were expecting just the non-inferiority benchmark to be met.

You need a license to cut-and-paste this copyrighted news content. Use this link to purchase your paid subscription ($200/year for individuals and $1,000/year for companies of every size): https://endpts.com/subscribe Already a paid subscriber? Sign in to Endpoints News to remove this message.

In the primary analysis of the intent-to-treat population, TransCon hGH demonstrated a significantly greater annualized height velocity of 11.2 cm/year compared to 10.3 cm/year for the daily hGH — the treatment difference amounted to 0.86 cm/year, hitting a p-value of 0.0088. The experimental treatment began to surpass the comparator at a statistically significant rate from week 26 onward.

Ascendis’ shares $ASND skyrocketed more than 64.6% in morning trading to $114.10.

“The stock is not cheap, but we do see room for significant upside upon positive pivotal data that may be used for registration of the first long-acting growth hormone treatment, which has been a prized goal for many companies over several decades,” Leerink’s Joseph Schwartz wrote in a note in late January.

The company, which has partnered with Roche’s Genentech and Sanofi to evaluate its technology for ophthalmology and diabetes drugs respectively, plans to submit a marketing application for its pediatric GHD product in the first half of 2020.

“Ascendis’ management continues to deliver with this best-case outcome for TransCon hGH in a Ph3 trial, further validating the technology platform and with positive read-through to other clinical programs and pipeline potential. We also see the positive Ph3 raising the company’s profile as a potential acquisition target, as Ascendis offers balanced clinical pipeline with fairly de-risked programs, potential best-in-class assets, an emerging new therapeutics vertical and plenty of optionality within the TransCon technology platform,” Credit Suisse analysts wrote in a note.

Top-line data for the fliGHt Trial, evaluating TransCon hGH in subjects who switch from daily hGH, are expected in the second quarter. The company is also evaluating its technology for use in hypoparathyroidism and achondroplasia.

[healthcaremarketresearch201-blog]

Parathyroid Disease Treatment Market Size Statistics, Facts and Figures

Parathyroid Disease Treatment Market: Introduction

Parathyroid disease is characterized with abnormalities of serum calcium. Hyperparathyroidism, hypoparathyroidism, and parathyroid cancer are the three types of parathyroid disease. Primary hyperparathyroidism is a condition, in which too much parathyroid hormone is produced by the parathyroid gland. Parathyroid cancer is a rare disease often caused due to high level of parathyroid hormone. A study published in BMC Endocrine Disorder stated that parathyroid cancer is a rare endocrine malignancy primarily diagnosed in patients with primary hyperparathyroidism.

View Report :  https://www.transparencymarketresearch.com/parathyroid-disease-treatment-market.html

Key Drivers and Opportunities of Global Parathyroid Disease Treatment Market

Rise in prevalence of parathyroid diseases is anticipated to boost the growth of the global parathyroid disease treatment market. An article published in PLOS, a study between 2003 and 2017, estimated that 13,897 admissions corresponding to 12,903 patients registered with parathyroid gland disorder were reported in Spain. According to Informa UK Limited, primary hyperparathyroidism (pHPT) is the third most common endocrine disorder.

Parathyroid problems are more common in younger adults (30 to 40 years) and older people. Hence, increase in the geriatric population is likely fuel the growth of the global market. According to an article published in journal of the Endocrine Society, a retrospective survey was conducted during January 1997 to June 2018, which estimated that 462 patients were diagnosed with primary hyperparathyroidism and 212 of them were aged above 65.

Focus on research & development by key players is anticipated to drive the global parathyroid disease treatment market. In June 2017, Amgen, Inc. received positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Marketing Authorization of a pediatric formulation, Mimpara (cinacalcet), for children aged three years and older with secondary hyperparathyroidism (HPT).

However, product recall by the Food and Drug Administration is likely hamper the growth of the global parathyroid disease treatment market. For instance, in September 2019, the Takeda Pharmaceutical Company Limited issued the U.S. recall of NATPARA.

Increase in awareness about advanced therapeutics owing to rise in prevalence of parathyroid diseases in developing countries presents lucrative opportunities in the global market. Moreover, governments in developing countries are making significant investments toward modernization of health care infrastructure, which is likely to increase access to health care. This is expected to drive demand for advanced technologies.

Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) :  https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=76800

North America to Capture Major Share of Global Parathyroid Disease Treatment Market

North America is likely to account for major share of the global parathyroid disease treatment market during the forecast period due to high prevalence of parathyroid diseases. Additionally, well-established health care infrastructure in developed countries is projected to boost the growth of the market in the region.

The parathyroid disease treatment market in Asia Pacific is expected to grow at a rapid pace during the forecast period owing to rise in awareness and surge in geriatric population. An article published in the Indian Journal of Endocrine Metabolism stated that the incidence of asymptomatic primary hyperparathyroidism has been rising in the West, including India.

Key Players Operating in Global Parathyroid Disease Treatment Market

The global parathyroid disease treatment market is highly consolidated due to the presence of small number of key players. Demand for parathyroid treatment products has increased in emerging as well as developed markets owing to rise in prevalence of parathyroid gland disorder. Growth strategies adopted by leading players are likely to drive the global market.

REQUEST FOR COVID19 IMPACT ANALYSIS – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=76800

Major players operating in the global parathyroid disease treatment market are:

Amgen Inc.

Novartis AG

Global Parathyroid Disease Treatment Market: Research Scope

Global Parathyroid Disease Treatment Market, by Treatment

SurgeryMinimally Invasive Parathyroidectomy

Standard Neck Exploration

Others

TherapeuticsCalcimimetics

Bisphosphonates

Plicamycin

Hormone Replacement Therapy

Others

Global Parathyroid Disease Treatment Market, by Application

Hyperparathyroidism

Parathyroid Cancer

Hypoparathyroidism

Global Parathyroid Disease Treatment Market, by Region

North AmericaU.S.

Canada

EuropeGermany

France

U.K.

Italy

Spain

Rest of Europe

Asia PacificChina

Japan

India

Australia & New Zealand

Rest of Asia Pacific

Latin AmericaBrazil

Mexico

Rest of Latin America

Middle East & AfricaGCC Countries

South Africa

Rest of Middle East & Africa

More Trending Reports by Transparency Market Research – 1. https://www.prnewswire.com/news-releases/global-radiation-therapy-market-to-reach-us-8-6-bn-by-2026–product-approvals-to-drive-growth-transparency-market-research-300998453.html

2. https://www.biospace.com/article/dna-test-kits-market-increase-in-demand-for-ancestry-testing-to-drive-market/

[market-insights-dbmr]

Global Orphan Drug Market 2019 Worldwide Robust Expansion by Top Key Manufactures, Overview, Size, Share, Trends, Segments, Demand and Forecast to 2025

Global orphan drug market is rise gradually to an estimated value of USD 326.25 billion by 2026 registering a CAGR of 8.5% in the forecast period of 2019-2026. Growing number of orphan diseases, accelerating novel therapies and orphan drug development programs and exclusive incentives from the government are the key factors for market growth.

Get Sample Copy Of This Report @  https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-orphan-drugs-market

Few of the major competitors currently working in the global  orphan  disease market are F. Hoffmann-La Roche Ltd.,  Novartis AG, Pfizer Inc., AbbVie, AstraZeneca, Baxter, Eli Lilly and Company, Johnson & Johnson Services Inc., Merck KGaA, Novo Nordisk A/S, Bristol-Myers Squibb Company, Alexion Pharmaceuticals, Kyowa Hakko Kirin Co., Ltd., Amgen Inc., Biogen, Celldex Therapeutics, GlaxoSmithKline plc., Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated (US)  and among others.

Key Developments in the Market:

In August 2018, Kyowa Hakko Kirin Co., Ltd received the FDA approval for Poteligeo (mogamulizumab-kpkc) injection, an Orphan Drug, for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sezary syndrome which are the types of non-Hodgkin lymphoma

In August 2018, Takeda Pharmaceutical Company Limited received FDA approval for Takhzyro (lanadelumab-flyo) injection for the treatment to hereditary angioedema (HAE) attack in patients 12 years of age and older

In June, 2018, Ascendis Pharma A/S received the FDA Orphan Drug Designation for TransCon PTH for the treatment of hypoparathyroidism. TransCon PTH is a long acting parathyroid hormone replacement therapy which helps in restoring the activity of parathyroid hormone

Competitive Analysis:

Global orphan drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of orphan drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Inquiry For Customize Report With Discount at : https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-orphan-drugs-market

Segmentation: Global Orphan Drug Market

By Disease Type

(Oncology disease, Metabolic Disease, Hepatology, Immunology, Infection, Neurology and Others),

Drug Type

(Biological, Non-Biological, and Others),

Indication Type

(Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Cystic Fibrosis, Glioma, Pancreatic Cancer, Ovarian Cancer, Multiple Myeloma, Duchenne Muscular Dystrophy, Renal Cell Carcinoma and Others),

Drug class

(Lenalidomide, Rituximab, Glatiramer Acetate, Nivolumab, Interferon Beta-1a, Ibrutinib, Cinacalcet Hydrochloride, Imatinib Mesylate, Bortezomib, Sodium Oxybate and Others),

Therapy Type

(Medication, Surgery and Others),

Route of Administration

(Oral, Intravenous and Others),

End- users

(Hospitals, Homecare, Specialty Clinics, Others),

Geography

(North America, South America, Europe, Asia-Pacific, Middle East and Africa)

Get Full Table Of content @   https://www.databridgemarketresearch.com/toc/?dbmr=global-orphan-drugs-market

Contact:

Data Bridge Market Research Tel: [phone] Email: [email protected]

[researchtrendingmarket-blog]

Hypoparathyroidism Drug Market - Industry Trends - Forecast to 2026

Global hypoparathyroidism drug market is expected to grow at a substantial growth of 8.1% CAGR in the forecast period of 2019-2026.  The emergence of drugs used in thyroid diseases, increases number of   thyroid cancer, development of newer technologies and vulnerable hypoparathyroidism patients enhancing the market growth.

Get Sample Report at :

https://bit.ly/31uI2N1

#Hypoparathyroidism Drug Market #Hypoparathyroidism Drug Market share #Hypoparathyroidism Drug Market size #Hypoparathyroidism Drug Market trends #Hypoparathyroidism Drug Market news #Hypoparathyroidism Drug Market report #Hypoparathyroidism Drug Market growth

[ajjpatil]

Hypoparathyroidism Treatment Market 2019- Global Industry Details by Overview, Size, Top Manufacturers, Trends, Demand, Overview, Forecast to 2025

Hypoparathyroidism Treatment Market By Drug Class (Vitamin D Analogue, Parathyroid Hormone, Calcium Supplements) Route of Administration (Parenteral, Oral) Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Sales) - Global Industry Analysis & Forecast to 2025

Industry Outlook and Trend Analysis

The Hypoparathyroidism Treatment Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. The uncommon condition named hypoparathyroidism includes the decrease in the activity parathyroid organs. The most well-known way a patient can experience the ill effects of hypoparathyroidism is after the parathyroid organs get expelled or harmed amid medical procedure. It is a condition of low parathyroid hormone discharge and can cause an extreme drop in calcium levels in the blood and also elevated amounts of phosphorus in the blood. Side effects for hypoparathyroidism run from mellow shivering in fingers, hands, or the mouth, to more genuine and agonizing muscle cramps. Exceptionally uncommon indications displayed by patients incorporate spasms and outrageous muscle cramping of the entire body.

Get Full Report: https://www.crystalmarketresearch.com/report/hypoparathyroidism-treatment-market

Drivers and Restraints

The developing screening rates, expanding number of thoracic medical procedures and occurrence of disease are anticipated to be the prime elements driving the development of the hypoparathyroidism treatment market. Thyroid or neck surgery is related with hypoparathyroidism, inferable from harm to the parathyroid organs. The quantity of thyroidectomies in the U.S. reflects 39% expansion from 2007 to 2015. Expanding interests in the innovative work combined with the advancement of biologics is foreseen to produce energy and development opportunities for the hypoparathyroidism treatment market.

Regional Insights

North America will be the potential market for the players as there is major demand for the product, and the players are also coming with new product with proper FDA approval.

By Region

·         North America

o   U.S.

o   Canada

o   Mexico

·         Europe

o   Germany

o   UK

o   France

o   Russia

o   Italy

o   Rest of Europe

·         Asia-Pacific

o   China

o   Japan

o   South Korea

o   India

o   Southeast Asia

o   Rest of Asia-Pacific

·         South America

o   Brazil

o   Argentina

o   Columbia

o   Rest of South America

·         Middle East and Africa

o   Saudi Arabia

o   UAE

o   Egypt

o   Nigeria

o   South Africa

o   Rest of MEA

Competitive Analysis                         

The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

F. Hoffmann-La Roche Ltd

WCCT GLOBAL INC

Novartis AG

Shire-NPS Pharmaceuticals, Inc

EnteraBio Ltd

Takeda Pharmaceutical Company Limited

GlaxoSmithKline plc

Some of the key questions answered by the report are:

What was the market size in 2014 and forecast from 2015 to 2025?

What will be the industry market growth from 2015 to 2025?

What are the major drivers, restraints, opportunities, challenges,     and industry trends and their impact on the market forecast?

What are the major segments leading the market growth and why?

Which are the leading players in the market and what are the major     strategies adopted by them to sustain the market competition?

About Crystal Market Research: Crystal offers one stop solution for market research, business intelligence, and consulting services to help clients make more informed decisions. It provides both syndicated as well as customized research studies for its customers spread across the globe. The company offers market intelligence reports across a broad range of industries including healthcare, chemicals & materials, technology, automotive, and energy.

Contact Us

Judy S 304 South Jones Blvd, Suite 1896, Las Vegas NV 89107, United States Toll Free: [phone] Email: [email protected]

#Hypoparathyroidism Treatment Market

[alwayssweatycolor]

Hypoparathyroidism Treatment Market Trends and Predictions Explore By Emerging Players - Sun Pharmaceutical Industries Ltd., AbbVie Inc.

50% of the Revenue Contribution by the Leading Players

The hypoparathyroidism treatment market is largely dominated by the major players, who are competing on the basis of market penetration and distribution. The consolidated nature of the hypoparathyroidism treatment market increases the profitability. Factors such as poor efficacy and efficiency of the treatment are hampering the adoption of hypoparathyroidism treatment. However, the growing awareness regarding hypoparathyroidism treatmentand number of thyroid surgeries are expected to create growth opportunities for the manufacturers operating in the global hypoparathyroidism treatment market. Shire-NPS Pharmaceuticals, Inc., EnteraBio Ltd., and Teva Pharmaceutical Industries Ltd. hold more than 50% revenue share in the global hypoparathyroidism treatment market. The growth of the global hypoparathyroidism treatment market is primarily driven by growing prevalence of hypoparathyroidism and increasing number of thoracic surgeries and incidence of cancer. Thedevelopment of healthcare infrastructure across the globe coupled with governmental support for hypoparathyroidism treatment is expected to drive the growth of the hypoparathyroidism treatment market. The companies operating in the market are involved in developing new experimental hypoparathyroidism treatment drugs.

Increasing Number of Thoracic Surgeries and Incidence of Cancer

The growing screening rates, increasing number of thoracic surgeries and incidence of cancer are expected to be the prime factors driving the growth of the hypoparathyroidism treatment market. Thyroid or neck surgery is associated with hypoparathyroidism, owing to damage to the parathyroid glands. The number of thyroidectomies in the U.S. reflects 39% increase from 2007 to 2015. This indicates transient post-surgical hypoparathyroidism, which can become permanent in about 25% of cases. The growing incidence of head & neck and thyroid cancers is the other factor expected to drive the growth of the market.

Increasing investments in the research and development coupled with the development of biologics is expected to generate momentum and growth opportunities for the hypoparathyroidism treatment market.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7857

New Drug Development and Government Support to Root Out Hypoparathyroidism

New drug development is expected to create enormous growth opportunity for the hypoparathyroidism treatment market. Any new curative hypoparathyroidism treatment drug is expected to witness fast adoption with minimal resources due to lack of competition in the hypoparathyroidism treatment market. Symptomatic treatment is the chief goal of hypoparathyroidism treatment as there is no treatment for hypoparathyroidism.

The support to hypoparathyroidism treatment products and initiatives by the governments of different countries such as financial incentives and orphan status are the other factors expected to boost the growth of the hypoparathyroidism treatment market. The demographic drivers of the hypoparathyroidism treatment market include growing geriatric population and healthcare expenditure across the globe.

Growing Purchasing Power and Attractive Reimbursements

In the North America hypoparathyroidism treatment market, the U.S. is expected to be the dominant country as it is a large economy and with high purchasing power. Besides, favorable reimbursements for hypoparathyroidism treatment is also expected to support the growth of the hypoparathyroidism market. Likewise, large presence of major players such as Shire-NPS Pharmaceuticals, Inc., and EnteraBio Ltd., among others, is also expected to drive the growth of the hypoparathyroidism treatment market in the U.S. The healthcare expenditure in the U.S. was almost 16% of its GDP in 2017, which reflects better pricing and market attractiveness for the hypoparathyroidism treatment market.

Request to View Methodology @ https://www.futuremarketinsights.com/askus/rep-gb-7857

Orphan Status and Incentives

The U.S. FDA’s orphan status to drugs and biologics that affect less than 200,000 people in the U.S. confer various incentives such as tax credits for qualified clinical trials and market exclusivity upon regulatory approval. In the hypoparathyroidism treatment market, Natpara is an approved drug with a black box warning notified by the U.S. FDA in January 2015 – enjoying an exclusivity period till 2022.

Competitive Landscape

This section of the report features the profiles of the key players in the hypoparathyroidism treatment market based on their market shares, differential strategies, product offerings, marketing approach and company dashboard. The key players operating in the hypoparathyroidism treatment market include Shire-NPS Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Teva Pharmaceutical Industries Ltd., and EnteraBio Ltd.

#Hypoparathyroidism Treatment Market

[pragya1-blog]

Parathyroid Hormone Market by Application, Trends and Growth Rate to 2026

Parathyroid hormone is a single chain polypeptide made up of 84 amino acids secreted by the parathyroid gland located near the thyroid gland. Inadequate secretion of parathyroid hormone results in the development of diseases related to bone such as osteoporosis, hypocalcaemia, and hyperphosphetemia. Parathyroid hormone controls the distribution of phosphate and calcium in the body. Hypoparathyroidism is a condition, wherein parathyroid glands do not produce sufficient amount of parathyroid hormone (PTH). The disease is characterized by low level of calcium and high levels of phosphate in the blood. According to statistics by Verdict Media Limited., approximately 100,000 people in the U.S. are diagnosed with hyperparathyroidism.

Obtain Report Details @

https://www.transparencymarketresearch.com/parathyroid-hormone-market.html

Increase in incidence and prevalence of conditions related to the imbalance in the parathyroid hormone level in the body due to changing lifestyles, surge in R&D on the development of parathyroid hormone analogues, and improved diagnostic procedures for the detection of parathyroid hormone imbalance are projected to drive the global parathyroid hormone market during the forecast period. In April 2017, Shire plc received approval from the European Commission for Natpar (rhPTH[1-84]). It is the first recombinant human protein with the full length 84-amino acid sequence of endogenous parathyroid hormone (PTH). Moreover, hypoparathyroidism is a rare disease. Hence, the products developed for its treatment are getting orphan drugs designation, leading to increase in research and development in this therapy area. However, complicated process of product development, high cost of manufacturing, and increasingly stringent regulatory requirements are anticipated to restrain the market during the forecast period.

The global parathyroid hormone market can be segmented based on product type, indication, end-user, and region. In terms of product type, the parathyroid hormone market can be bifurcated into recombinant parathyroid hormones and parathyroid hormone analogues. The parathyroid hormone analogues segment includes teriparatide and abaloparatide. Based on indication, the global parathyroid hormone market can be classified into hypoparathyroidism, osteoporosis, and postmenopausal bone complications. In terms of end-user, the parathyroid hormone market can be divided into hospitals, clinics, and others. The hospitals segment is anticipated to account for major parathyroid hormone market share during the forecast period. However, the clinics segment is likely to expand at the highest CAGR from 2018 to 2026 owing to rise in patient preference for clinics due to improved medical services, cleanliness, and favorable reimbursement scenario.

Request Report Brochure @

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=57732

Based on region, the global parathyroid hormone market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global parathyroid hormone market owing to high incidence rate of hypoparathyroidism, increase in health care spending, rise in investment in research related to parathyroid hormone product development by players, and surge in new product approvals in the region. Europe is anticipated to be the second largest market for parathyroid hormone in terms of revenue during the forecast period. Presence of large geriatric population is expected to propel the market in the region. The parathyroid hormone market in Asia Pacific is likely to expand at the highest CAGR due to economy growth and rise in health care expenditure in the developing countries.

Enquiry for Discount on this Report @

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=57732

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research State Tower, 90 State Street, Suite 700 Albany, NY 12207 United States Tel: [phone] USA - Canada Toll Free: 866-552-3453 Email: [email protected] Website: www.transparencymarketresearch.com

#Parathyroid Hormone Market